Chembio Diagnostics (CEMI: Pinksheets)—Announced total revenues were $3.64 million for the quarter ended March 31, 2011, which compares to total revenues of $2.78 million for the quarter ended March 31, 2010, a 30.6% increase. The Company recorded a net loss of approximately $.14 million, or less than a $0.01 per share, for the quarter ended March 31, 2011, compared to a net loss of approximately $.15 million, or less than $0.01 per share, for the quarter ended March 31, 2010. The 36% increase in Net Product Sales during the first quarter was as a result of a 77% increase in sales to Alere, Inc. of our FDA-approved rapid HIV tests for marketing in the U.S., continuing the pace of sales during the fourth quarter of 2010 and reflecting continued success of these products. CEMI closed Friday at $.51 unchanged and up 24% since we added it to our watch list on 11/16/10.